Bayer consolidates $2.4 billion U.S. glyphosate business into new Ruveon unit

Bayer has consolidated its U.S. glyphosate business, including the Roundup brand, into a new standalone entity called Ruveon, based in St. Louis, Missouri. Announced on July 1, the move folds pricing, go-to-market strategy, production and logistics for U.S. glyphosate into a single business that remains part of Bayer Group.

The restructuring is an executional step within the Crop Science division’s Five-Year Framework, Bayer’s plan to sharpen focus and profitability in a competitive crop protection market. Glyphosate generated about $2.4 billion in revenue for Bayer in 2024. Ruveon is led by chief executive Alfonso Alba Ordóñez, a 30-year Bayer veteran, with Steve Knodle as executive vice president for commercial business.

“Today we take an important step within our Five-Year Framework,” said Brian Naber, head of Crop Science for North America and Australia/New Zealand. The company positioned Ruveon as a nimbler player in a commodity market facing litigation, regulatory scrutiny and competition from generic suppliers.

The reorganization landed one week after the U.S. Supreme Court ruled 7-2 in Bayer’s favor, finding that federal pesticide law preempts state failure-to-warn claims over Roundup. In parallel, Bayer and Ruveon have petitioned the Commerce Department, the U.S. International Trade Commission and the Court of International Trade for antidumping and countervailing duties on Chinese glyphosate, alleging dumping margins from roughly 69% to more than 446%. The petition has drawn pushback from some farm groups.